Evidence map›Paper›PMID 40601153›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

Cytokine Antibody Microarray-Based Proteomic Strategies for Characterizing the Dysregulation of Cytokines Disease-Specific.

Rodrigo Barderas, Pablo San Segundo-Acosta, Ana Montero-Calle

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rodrigo BarderasFunctional Proteomics Unit, Chronic Disease Programme (UFIEC), Instituto de Salud Carlos III, Madrid, Spain. r.barderasm@isciii.es.ORCID https://orcid.org/0000-0003-3539-7469
Pablo San Segundo-AcostaFunctional Proteomics Unit, Chronic Disease Programme (UFIEC), Instituto de Salud Carlos III, Madrid, Spain.ORCID https://orcid.org/0009-0000-1951-1423
Ana Montero-CalleFunctional Proteomics Unit, Chronic Disease Programme (UFIEC), Instituto de Salud Carlos III, Madrid, Spain.ORCID https://orcid.org/0000-0001-5141-0454

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The understanding of disease mechanisms and the search for potential therapeutic targets have driven the focus of proteomics studies towards the identification of specific protein profiles and molecular pathways disease associated. Protein microarrays offer high-throughput alternatives to mass spectrometry, with peptide, phage, and recombinant protein microarrays providing different options for studying disease-specific alterations. Commercially available antibody microarrays, particularly cytokine arrays, enable the simultaneous analysis of multiple cytokine expression levels, offering valuable insights into disease processes, drug efficacy, and biomarker discovery. Indeed, cytokine arrays outperform mass spectrometry methods due to their ability to analyze cytokines at an extremely low concentration in parallel in a high-throughput manner. Here, we outline protocols for cytokine analysis using cytokine antibody microarrays, detailing sandwich approaches and direct or indirect incubation methods for the characterization of disease-associated cytokine profiles.

Indexed as

AntibodiesCytokinesProtein Array AnalysisProteomicsBiomarkersHumansAntibodiesBiomarkersCytokinesAntibody microarrayCytokine arrayCytokinesGrowth factorsProteomics immunomodulatorsScreening

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.